U.S. Food and Drug Administration approved Keytruda (pembrolizumab) for intravenous injection for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer. This marks the first immunotherapy approved for this patient population as a first-line treatment and which is administered to patients without also giving chemotherapy.
source https://www.pharmatutor.org/pharma-news/2020/fda-approves-first-line-immunotherapy-for-patients-with-msi-h-dmmr-metastatic-colorectal-cancer
No comments:
Post a Comment